Core Insights - United Laboratories International Holdings Ltd. and Novo Nordisk A/S have reported positive topline results from a phase 2 trial of UBT251, a triple agonist for type 2 diabetes treatment [1] Group 1: Trial Overview - The phase 2 trial involved once-weekly injectable doses of UBT251 (2 mg, 4 mg, and 6 mg) compared to placebo and Semaglutide 1 mg in Chinese patients with type 2 diabetes [2] - The primary endpoint was the change in HbA1c from baseline after 24 weeks, with baseline averages of HbA1c at 8.12%, body weight at 80.1 kg, and BMI at 29.1 kg/m² [2] Group 2: Efficacy Results - UBT251 achieved a mean reduction in HbA1c of 2.16%, outperforming Semaglutide (1.77%) and placebo (0.66%) [3] - UBT251 also resulted in a body weight reduction of up to 9.8%, compared to 4.8% for Semaglutide and 1.4% for placebo [3] Group 3: Secondary Endpoints and Safety - UBT251 showed improvements over placebo in key secondary endpoints, including waist circumference, blood pressure, and lipid levels [4] - The safety and tolerability profile of UBT251 was consistent with previous clinical trials of triple-G agonists [4] Group 4: Future Development Plans - United Biotechnology plans to initiate two phase 3 trials with UBT251 in Chinese patients with type 2 diabetes [5] - Novo Nordisk intends to start a global phase 2 trial with UBT251 later this year, alongside an ongoing global phase 2 trial in weight management with results expected next year [5] Group 5: Competitive Landscape - Eli Lilly's Retatrutide is noted as the most advanced triple-G agonist, having shown significant reductions in HbA1c and weight in its phase 3 trial for type 2 diabetes [6] - In the TRANSCEND-T2D-1 study, Retatrutide reduced HbA1c by 1.7% to 2.0% and participants on the 12 mg dose lost an average of 36.6 lbs (16.8%) [7]

Investment Rating - The report maintains a "Strong Buy" rating for the pharmaceutical industry, indicating a positive outlook compared to the market [3]. Core Insights - The report highlights the approval of the world's first invasive brain-computer interface (BCI) medical device for clinical application, marking a significant milestone in the industry [37]. - The implementation of DRG/DIP 3.0 is scheduled for January 2027, which is expected to optimize payment grouping rules and enhance the integration of DRG/DIP systems [38]. Market Performance - The pharmaceutical and biotechnology index fell by 2.77% this week, underperforming the CSI 300 index by 0.59 percentage points, ranking 8th in industry performance [14]. - Year-to-date, the pharmaceutical index has decreased by 2.9%, also lagging behind the CSI 300 index by 1.54 percentage points, ranking 20th [14]. Sub-industry Analysis - Among sub-industries, traditional Chinese medicine fell by 1.16%, biological products by 1.79%, chemical pharmaceuticals by 2.08%, medical devices by 4%, pharmaceutical commerce by 4.01%, and medical services by 4.32% [20]. - The medical device sector has shown the smallest decline year-to-date at -0.38%, while the chemical pharmaceutical sector has experienced the largest drop at -6.05% [20]. Notable Company Developments - Shanghai Ladder Medical Technology completed a strategic financing round of 500 million yuan, accelerating its clinical progress in brain-computer interface technology [34]. - Eli Lilly announced a plan to invest $3 billion over the next decade to expand its supply chain in China, focusing on local production capabilities for oral solid formulations [33].

Investment Rating - The report maintains a "Strong Buy" rating for the pharmaceutical industry, indicating a positive outlook compared to the market [3]. Core Insights - The report highlights the approval of the world's first invasive brain-computer interface (BCI) medical device, marking a significant milestone in clinical applications [9][35]. - The implementation of DRG/DIP 3.0 is scheduled for January 2027, which is expected to optimize payment grouping rules and enhance the efficiency of healthcare funding [38]. Market Performance - The pharmaceutical index decreased by 2.77% this week, underperforming the CSI 300 index by 0.59 percentage points, ranking 8th in industry performance [14]. - Year-to-date, the pharmaceutical index has declined by 2.9%, also trailing the CSI 300 index by 1.54 percentage points, ranking 20th [14]. Sub-industry Analysis - Among sub-industries, traditional Chinese medicine fell by 1.16%, biological products by 1.79%, chemical pharmaceuticals by 2.08%, medical devices by 4%, pharmaceutical commerce by 4.01%, and medical services by 4.32% [20]. - The medical device sector has shown the smallest decline year-to-date at -0.38%, while the chemical pharmaceutical sector has experienced the largest drop at -6.05% [20][23]. Notable Company Developments - Shanghai Ladder Medical Technology completed a strategic financing round of 500 million yuan, enhancing its clinical trial progress in the brain-computer interface sector [34]. - Eli Lilly announced a plan to invest $3 billion over the next decade to expand its supply chain in China, focusing on local production capabilities for its oral GLP-1 receptor agonist [33]. Industry News and Policies - Jiangsu Province has released an action plan for the innovative development of the brain-computer interface industry, aiming for breakthroughs in technology and the establishment of industrial clusters by 2027 [33]. - The National Medical Insurance Administration has provided updates on the DRG/DIP 3.0 version, which will enhance the payment system for hospital services [38].

Investment Rating - The industry investment rating is "stronger than the market" (预计6个月内，行业指数表现强于市场表现5%以上) [34] Core Insights - The domestic pharmaceutical industry is showcasing innovative pipelines at the 2026 AACR conference, indicating a strong competitive edge globally [5] - Investment strategies suggest focusing on innovative treatment areas such as metabolic diseases, chronic diseases, and central nervous system disorders, as well as potential technology platforms like small nucleic acid drugs and CAR-T therapies [6] - The report highlights a slight increase in pharmaceutical financing and a recovery in BD transactions and H-share IPOs, which are revitalizing innovation enthusiasm [6] Summary by Sections Industry Overview - The 2026 AACR conference will take place in San Diego, featuring numerous innovative pharmaceutical companies discussing breakthroughs from basic research to clinical translation [5] - Key presentations include Merck's disclosure of clinical data for MK-2010, Revolution's updates on Pan-Ras assets, and various other companies showcasing their clinical and preclinical data [5] Investment Strategy - The report recommends focusing on companies with strong potential in innovative drug development, including Baiyi Shenzhou, He Yu-B, and others [6] - It emphasizes the growth of external CXO demand and suggests monitoring companies involved in emerging fields like peptides and small nucleic acids [6] Market Performance - The pharmaceutical sector experienced a decline of 2.77% last week, while the Shanghai and Shenzhen 300 index fell by 2.19%, ranking the pharmaceutical industry 8th among 28 sectors [10][19] - The valuation of the pharmaceutical sector is reported at 28.87 times (TTM), with a premium of 6.85% over the overall A-shares [25]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical industry, indicating a positive outlook compared to the overall market performance [2][38]. Core Insights - The pharmaceutical sector experienced a decline of 2.8% this week, with the overall market indices also showing negative trends. The pharmaceutical index ranked 8th among 31 sub-industries [2][3]. - Recent fluctuations in chemical raw material prices have led to a reversal in prices for many active pharmaceutical ingredients (APIs) and intermediates, suggesting potential investment opportunities [12]. - Significant advancements in drug development were noted, including successful clinical trials for Pfizer's CDK4 inhibitor and other innovative treatments [17][21][23]. Market Performance - The pharmaceutical index fell by 2.8%, while the Shanghai Composite Index decreased by 3.4% and the Wind All A Index (excluding financials and petrochemicals) dropped by 4.5% [2][3]. - The overall valuation of the pharmaceutical sector stands at 29.5 times earnings, ranking 11th among 31 primary industries [6][16]. Recent Key Events - Pfizer's CDK4 inhibitor showed positive results in a Phase II trial for advanced breast cancer, significantly improving progression-free survival (PFS) [17]. - The KX-826 solution from 开拓药业 reached its primary endpoint in a Phase III trial for androgenetic alopecia, demonstrating a notable increase in hair count compared to the placebo group [21]. - Johnson & Johnson's Icotrokinra received FDA approval for treating moderate to severe plaque psoriasis, showcasing strong efficacy and safety profiles [22]. -礼来’s three-target agonist for type 2 diabetes achieved significant results in a Phase III trial, with participants experiencing an average A1C reduction of 2.0% and weight loss of 36.6 pounds [23]. Company Dynamics -沃森生物's controlling shareholder changed to 腾云新沃, which will hold a significant stake in the company following a stock issuance [26]. - Collegium announced the acquisition of AZSTARYS for $650 million, with potential additional payments based on future milestones [27]. IPO Dynamics - Upcoming IPOs include 德适-B and 同仁堂医养, both scheduled for March 30, 2026 [28].

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the biopharmaceutical sector [7] Core Insights - The report highlights the upcoming European Lung Cancer Conference (ELCC 2026) scheduled for March 25-28, 2026, in Copenhagen, Denmark, where significant data disclosures are expected from domestic companies [3][24] - Notable clinical trial results have been reported, including the final overall survival (OS) data for科伦博泰's TROP2 ADC sac-TMT in EGFR-mutant non-small cell lung cancer and 百利天恒's EGFR×HER3 dual antibody ADC iza-bren in extensive-stage small cell lung cancer [24][29] Summary by Sections Weekly New Drug Market Review - From March 16 to March 22, 2026, the top five gainers in the new drug sector were 三生国健 (+23.14%), 旺山旺水 (+12.90%), 派格生物医药 (+10.29%), 海思科 (+10.12%), and 泽璟制药 (+9.53%). The top five losers were 迈博药业 (-25.71%), 开拓药业 (-24.81%), 轩竹生物 (-14.00%), 药捷安康 (-10.50%), and 亚虹医药 (-10.30%) [19][21] Weekly Focus on Recommended Stocks - The report suggests focusing on stocks with potential catalysts, including: 1. Companies with overseas data catalysts: 贝达药业, 映恩生物, 和黄医药 2. Companies with MNC certification and high certainty for future overseas volume: 三生制药, 联邦制药, 科伦博泰 3. Potential heavyweights for overseas licensing by MNC: 复宏汉霖, 石药集团, 益方生物 4. New innovative drug technology breakthroughs: small nucleic acids, in vivo CAR-T, fat reduction and muscle gain, autoimmune CAR-T/dual antibodies, gene therapy [2][23] Weekly New Drug Industry Analysis - The report emphasizes the significance of the ELCC 2026 conference, where key data from clinical trials will be presented, showcasing the efficacy of new treatments in lung cancer [3][24] Weekly New Drug Approval & Acceptance Status - No new drug or new indication approvals were reported this week, but three new drug or new indication applications were accepted [31] Weekly New Drug Clinical Application Approval & Acceptance Status - A total of 63 new drug clinical applications were approved, and 27 new drug clinical applications were accepted this week [33]

Core Viewpoint - Eli Lilly has made significant progress in the metabolic field with its GIPR/GLP-1R/GCGR triagonist Retatrutide, which has shown positive results in the Phase III TRANSCEND-T2D-1 study for type 2 diabetes patients who struggle to control blood sugar through lifestyle changes alone [5][6]. Summary by Sections Efficacy and Safety - Retatrutide demonstrated a 2.0% average reduction in HbA1c levels compared to placebo after 40 weeks of treatment, along with an average weight loss of 36.6 pounds (approximately 16.8%) [5]. - The drug also showed significant improvements in cardiovascular metabolic risk factors, including non-HDL cholesterol, triglycerides, and systolic blood pressure, indicating its potential for broader metabolic management [6]. - Common adverse events were primarily gastrointestinal, including nausea, diarrhea, and vomiting, with incidence rates increasing with dosage: nausea (16.4%, 19.5%, 26.5% for 4mg, 9mg, and 12mg respectively), diarrhea (18.7%, 26.3%, 22.8%), and vomiting (15.7%, 15.0%, 17.6%) compared to 3.7%, 4.5%, and 2.2% in the placebo group [6][7]. Tolerability and Future Prospects - Discontinuation rates due to adverse events were 2.2%, 4.5%, and 5.1% for the 4mg, 9mg, and 12mg groups, respectively, indicating acceptable tolerability within the current market standards for effective weight loss and blood sugar-lowering medications [7]. - Retatrutide is being developed as a triple receptor agonist that activates GIPR, GLP-1R, and GCGR, which may enhance metabolic benefits compared to existing dual or single-target drugs [7][8]. - Eli Lilly is advancing multiple Phase III clinical trials for Retatrutide, targeting not only type 2 diabetes but also obesity, overweight with related conditions, knee osteoarthritis, moderate to severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-related fatty liver disease [8]. Upcoming Data and Implications - The detailed results of the TRANSCEND-T2D-1 study are expected to be presented at the American Diabetes Association scientific meeting in June, with further results anticipated within the next year [8]. - If subsequent results continue to show stability, Retatrutide could become a significant asset for Eli Lilly in reshaping the competitive landscape of metabolic diseases following the success of GLP-1 therapies [8].

Industry Insights - The global weight loss drug market is projected to reach approximately $130 billion by 2034, with a compound annual growth rate (CAGR) of 13%-15% from 2024 to 2034, driven by a low penetration rate of about 1% among the over 900 million obese individuals worldwide [2][5] - The clinical advantages of tirzepatide, a dual receptor agonist, have led to a significant market share, capturing 67% of new prescriptions and 63% of total prescriptions in the U.S. by October 2025 [2][5] - The expansion of insurance coverage and decreasing drug prices in the U.S. are expected to catalyze demand, with Medicare Part D now covering weight loss treatments for patients with comorbidities [5] Technological Advancements - The development of weight loss drugs is focusing on four key areas: long-acting formulations, oral administration, enhanced efficacy, and muscle preservation during weight loss [6] - Notable advancements include Pfizer's monthly GLP-1 and insulin formulations, and oral small molecule GLP-1 receptor agonists from companies like Eli Lilly and Mondelēz [6][7] Company Analysis - The report highlights the potential of Gako's JAB-23E73 (pan-KRAS) as a groundbreaking drug, showing promising early efficacy and safety compared to competitors [8][9] - JAB-23E73 has demonstrated a treatment-related adverse event rate of 11.9%, significantly lower than the 34% observed with RMC-6236, indicating a favorable safety profile [9] - Gako's financial position is robust, with a cash balance of 1.13 billion RMB and expected revenue from partnerships, positioning the company well for future growth [11]

Core Insights - Eli Lilly's stock has decreased by 2.9% year-to-date, currently priced around $1,044, while institutional investors have been increasing their holdings during this pullback [2]. Financial Performance - In Q4 2025, Eli Lilly reported revenue of $19.29 billion, surpassing the consensus estimate of $18.14 billion, and a non-GAAP EPS of $7.54, exceeding the estimate of $6.74 by nearly 12% [3]. - The previous quarter also saw revenue and EPS beats of 9.5% and over 19%, respectively, with prediction markets indicating a 99.9% probability of beating Q4 earnings [3]. Product Performance - Mounjaro generated $7.4 billion in Q4, reflecting a 110% year-over-year increase, while Zepbound contributed $4.2 billion, up 123% [4]. - Zepbound holds nearly 70% of new prescriptions in the branded obesity market, and Mounjaro commands over 55% of new prescriptions in the type 2 diabetes incretin market [4]. Institutional Ownership - Institutional ownership of Eli Lilly stands at 84.7%, with significant recent accumulation from various investors, including American Century and Andra AP fonden [5]. - The Wall Street consensus is overwhelmingly positive, with 24 buy ratings and only 1 sell, and an average price target of $1,214 [5]. Future Guidance - Management has guided for revenue between $80 billion and $83 billion in 2026, with non-GAAP EPS projected at $33.50 to $35.00 [6]. - The oral GLP-1 drug, orforglipron, is expected to receive FDA approval in Q2 2026, with a launch planned for chronic weight management in the US [6]. Research and Development - Retatrutide, a triple agonist, demonstrated an average weight loss of 29% at 68 weeks in the TRIUMPH-4 trial, along with a 76% reduction in knee pain scores [7]. - Eli Lilly's LillyPod supercomputer, built with Nvidia technology, is designed to enhance drug discovery through AI, making it the most powerful supercomputer owned by a pharmaceutical company [7]. Executive Activity - Eli Lilly's CEO and 12 executives collectively purchased $104 million in shares during February, indicating strong internal confidence in the company's future [8].

Summary of Conference Call Notes Company and Industry Involved - **Company**: 联邦制药 (Federation Pharmaceuticals) - **Industry**: Pharmaceutical Industry, specifically focusing on obesity treatment and antibiotic pricing Core Points and Arguments - **Clinical Trial Results for UBT251**: - On February 24, 2026, 联邦制药 announced the Phase 2 clinical data for UBT251 in China, which involved a randomized, double-blind, parallel, placebo-controlled trial with 205 participants suffering from obesity or overweight with related comorbidities [1] - The baseline average weight of participants was 92.2 kg, with an average BMI of 33.1 kg/m² [1] - Participants were randomly assigned to receive UBT251 injections (2 mg, 4 mg, 6 mg) or a placebo, administered weekly for 24 weeks [1] - **Weight Loss Efficacy**: - UBT251 showed an average weight loss of up to 19.7% across all dosage groups, compared to a 2.0% weight loss in the placebo group [2] - The adjusted weight loss for UBT251 after 24 weeks was 17.7%, which outperformed礼来的Retatrutide, which had an adjusted weight loss of 15.9% in its 8 mg dosage group [2] - **Safety Profile**: - The overall safety and tolerability of UBT251 were reported to be good, with no withdrawals due to adverse events [2] - Adverse events were similar to those of comparable drugs, primarily gastrointestinal reactions, mostly mild to moderate, with no unexpected safety issues reported [3] Other Important but Possibly Overlooked Content - **Antibiotic Pricing Trends**: - In early 2025, the price of 6-APA (an antibiotic precursor) stabilized, with market prices rising to 220 RMB/kg from 150 RMB/kg at the end of the previous year [3] - It is anticipated that the company's main business will see a certain recovery in 2026, although this is contingent on downstream acceptance [3]